IMG_20260712_000217_783.jpg
Also positive for rings and schizonts of plasmodium vivax
Reading File
Finding Sources
Finding Sources
Reading File
Finding Sources
Reading File
Finding Sources
I now have all the information needed. Here is a full clinical analysis:
CBC + Peripheral Smear Analysis: Plasmodium vivax Malaria
Patient: Mr. Sushant Dubey | 22 years, Male | Sample: 11 July 2026
CBC Findings - What Is Abnormal and Why
| Parameter | Result | Reference | Status | Clinical Significance |
|---|---|---|---|---|
| Haemoglobin | 12.40 g/dL | 13-18 | Low | Mild anaemia from RBC destruction by parasites |
| Packed Cell Volume | 33.22% | 35-60% | Low | Confirms anaemia |
| MCV | 56.21 fL | 76-97 fL | Very low | Microcytic - likely co-existing iron deficiency |
| MCH | 20.98 pg | 27-31 pg | Low | Hypochromic - supports iron deficiency |
| MCHC | 37.33% | 33-37% | Borderline high | |
| Platelet Count | 93,000/cumm | 1,50,000-4,50,000 | Significantly LOW | Malaria-associated thrombocytopenia |
| RDW | 19.30% | 11.5-16.5% | High | Anisocytosis - mixed picture (malaria + iron deficiency) |
| WBC | 7,400/cumm | 4,000-11,000 | Normal | |
| Differential | Within normal limits | - | Normal |
Key Interpretation
1. Thrombocytopenia (platelets = 93,000)
This is a hallmark finding in P. vivax infection. Thrombocytopenia in vivax malaria can be severe and is caused by:
- Immune-mediated platelet destruction (antibody-antigen complexes)
- Hypersplenism (spleen sequesters platelets)
- Platelet consumption
- Reduced thrombopoiesis due to bone marrow suppression
Per the Red Book 2021, thrombocytopenia is listed as a recognized complication specifically associated with P. vivax, and can occasionally be severe.
2. Peripheral Smear: Rings and Schizonts of P. vivax
- Ring stage (early trophozoite): Large rings, often with 2 chromatin dots; the infected RBC is enlarged (a key feature distinguishing vivax from falciparum)
- Schizonts: Presence of schizonts in peripheral blood is more typical of P. vivax (falciparum schizonts are usually sequestered). Vivax schizonts contain 12-24 merozoites arranged around a central malaria pigment clump (Schuffner's dots in infected RBCs)
- The smear confirms active, ongoing erythrocytic cycle
3. Microcytic Hypochromic Anaemia (MCV 56, MCH 21, RDW 19.3%)
This pattern (very low MCV, high RDW) points to a co-existing iron deficiency anaemia or possibly thalassaemia trait, separate from the malaria-related anaemia. Malaria itself typically causes normocytic anaemia. The microcytosis and raised RDW suggest mixed deficiency - malaria has unmasked or worsened an underlying iron deficiency.
Treatment Protocol (India - National Guidelines)
Per Park's Textbook of Preventive and Social Medicine:
Drug Schedule for P. vivax (adult, ≥15 years):
| Drug | Dose | Timing |
|---|---|---|
| Chloroquine (CQ) 150 mg base tablets | 10 mg/kg (4 tablets) | Day 1 |
| Chloroquine | 10 mg/kg (4 tablets) | Day 2 |
| Chloroquine | 5 mg/kg (2 tablets) | Day 3 |
| Primaquine (PQ) 2.5 mg tablets | 0.25 mg/kg/day (6 tablets/day) | Days 1-14 |
Total chloroquine dose = 25 mg/kg over 3 days - Park's Textbook, p. 307
Primaquine is given for 14 days to eradicate hypnozoites (dormant liver stage) and prevent relapse. Vivax relapse rate in India is ~30% without primaquine. The 14-day course must be given under supervision.
MANDATORY before Primaquine: Check G6PD status - primaquine causes severe haemolytic anaemia in G6PD-deficient patients. Signs of haemolysis to watch for: dark urine, jaundice, abdominal pain, bluish discolouration of lips.
Additional Management
- Antipyretics for fever (paracetamol preferred)
- Investigate for iron deficiency: Serum ferritin, serum iron, TIBC - given the striking microcytosis (MCV 56) which is too low for malaria alone
- Monitor platelets - currently 93,000 (not yet at bleeding risk, but needs monitoring). No specific platelet transfusion needed unless <20,000 or active bleeding
- Repeat CBC after completion of chloroquine (5-7 days) to ensure platelet recovery and haemoglobin stabilization
- Hepatic hypnozoite eradication with primaquine prevents future relapses (which can occur for up to 3 years without treatment)
- If patient does not respond within 72 hours of chloroquine, consider chloroquine resistance - rare in India but documented
Summary
This 22-year-old male has confirmed P. vivax malaria with:
- Active parasitaemia (rings + schizonts on smear)
- Malaria-associated thrombocytopenia (93,000) - expected and will recover with treatment
- Mild anaemia with a microcytic/hypochromic pattern suggesting concurrent iron deficiency (needs separate evaluation)
- Normal WBC and differential
Treatment: Chloroquine 25 mg/kg over 3 days + Primaquine 0.25 mg/kg/day x 14 days (after confirming normal G6PD). The platelet count and anaemia should both improve with successful parasite clearance.
This is a shared conversation. Sign in to Orris to start your own chat.